Login / Signup

Ultra-proactive therapeutic drug monitoring of infliximab based on point-of-care-testing in inflammatory bowel disease: results of a pragmatic trial.

Peter BossuytLieven PouillonSophie ClaeysSoetkin D'HaensEveline HoefkensBeatrijs StrubbeDenis MarichalHarald Peeters
Published in: Journal of Crohn's & colitis (2021)
Ultraproactive TDM in patients with IBD and maintenance IFX treatment leads to equal clinical outcomes as reactive TDM after one year of follow-up.
Keyphrases
  • study protocol
  • ulcerative colitis
  • clinical trial
  • phase iii
  • phase ii
  • open label
  • double blind
  • placebo controlled